文献速递产科母胎医学

早孕期早产型子痫前期筛查的质量评估

Quality assessment of first-trimester screening for preterm pre-eclampsia.
PubMed 文献 · Ultrasound Obstet Gynecol · 2022-01-01

单中心研究对单胎孕妇进行早产型子痫前期前瞻性筛查,采用母体特征、平均动脉压、子宫动脉多普勒搏动指数及血清标志物评估风险,风险高于1/200者建议每日服用150 mg可溶性阿司匹林至34周。估计检出率79.7%、假阳性率16.2%,实际患病率为预期的62%(95%CI 23-140%),研究不足以评估筛查影响。

要点

  • 早产型子痫前期筛查估计检出率79.7%,假阳性率16.2%。
  • 风险高于1/200者建议每日150 mg可溶性阿司匹林至34周。
  • 实际患病率为预期的62%(95%CI 23-140%),研究不足以评估筛查影响。

核心结论

  • 单中心可在筛查妇女少于2000例的条件下估计早产型子痫前期筛查的性能,但评估筛查对患病率的影响需要更大的队列。

研究设计与样本

  • 单中心研究,前瞻性筛查单胎孕妇的早产型子痫前期(即37周前分娩),使用母体特征、平均动脉压、子宫动脉多普勒搏动指数、母体血清妊娠相关血浆蛋白A和胎盘生长因子。

主要发现

  • 平均动脉压、子宫动脉多普勒搏动指数和血清标志物的分布与风险模型参数一致。
  • 估计检出率为79.7%,假阳性率为16.2%。
  • 共有6例早产型子痫前期,其中4例发生在筛查阳性的妇女中。
  • 患病率为预期的62%,但95%CI为23-140%,表明研究不足以评估筛查影响。

关键数值与推荐

  • 风险高于1/200者建议每日服用150 mg可溶性阿司匹林直至34周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究不足以评估筛查对患病率的影响(95%CI 23-140%),需要更大的队列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the performance and impact of first-trimester preterm pre-eclampsia screening in a single center. METHODS: This was a single-center study of women with a singleton pregnancy who were screened prospectively for preterm pre-eclampsia (i.e. delivery before 37 weeks' gestation) using maternal characteristics, mean arterial pressure (MAP), uterine artery Doppler pulsatility index, maternal serum pregnancy-associated plasma protein-A and placental growth factor. The individual risk for preterm pre-eclampsia was estimated from a published model, and those with a risk above 1 in 200 were recommended to take 150 mg soluble aspirin per day until 34 weeks. Information on the incidence of pre-eclampsia was obtained from the hospital register of adverse pregnancy outcomes. Screening performance indicators, including detection and false-positive rates, were estimated from the distribution of risks. Screening impact was estimated by dividing the observed prevalence by the expected prevalence, which was derived from the distribution of risks. RESULTS: The distributions of MAP, uterine artery Doppler pulsatility index and serum markers were consistent with the risk model parameters. The estimated detection and false-positive rates were 79.7% and 16.2%, respectively. There were six cases of preterm pre-eclampsia, four of which occurred in women with a positive screening result. The prevalence was 62% of that expected, but the 95% CI of 23-140% indicated that the study was underpowered to assess the impact. CONCLUSIONS: This study demonstrates that the performance of preterm pre-eclampsia screening can be estimated in a single center with fewer than 2000 women screened. However, in order to assess the impact of screening on the prevalence of the condition, a much larger cohort is needed. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Dhaifalah I, Magalova E, Studnykova D, et al. Quality assessment of first-trimester screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2022. PMID: 35633510. doi:10.1002/uog.24956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。